𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Impaired platelet aggregation in melanoma patients treated with interferon-α-2b adjuvant therapy

✍ Scribed by Haim Gutman; Jacob Schachter; Ella Stopel; Roee Gutman; Judith Lahav

Publisher
John Wiley and Sons
Year
2002
Tongue
English
Weight
125 KB
Volume
94
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The feasibility of adjuvant interferon α
The feasibility of adjuvant interferon α-2b in children with high-risk melanoma
✍ Fariba Navid; Wayne L. Furman; Martin Fleming; Bhaskar N. Rao; Sandra Kovach; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND It has been shown that induction high‐dose interferon α‐2b (IFN‐α‐2b) followed by maintenance therapy improves recurrence‐free survival in adults with high‐risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnos

Practical guidelines for the management
Practical guidelines for the management of interferon-α-2b side effects in patients receiving adjuvant treatment for melanoma : Expert opinion
✍ Axel Hauschild; Helen Gogas; Ahmad Tarhini; Mark R. Middleton; Alessandro Testor 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Abstract Interferon‐α‐2b (IFNα2b) is the only effective adjuvant therapy for melanoma patients at high risk of recurrence that has been approved by regulatory authorities worldwide. However, IFN toxicities increase the risk of poor treatment compliance and impair the potential for benefit from t

Temozolomide in combination with interfe
Temozolomide in combination with interferon α-2b in patients with metastatic melanoma : A Phase I dose-escalation study
✍ Sanjiv S. Agarwala; John M. Kirkwood 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 100 KB 👁 1 views

## Abstract ## BACKGROUND Metastatic melanoma (MM) is associated with a high risk of central nervous system (CNS) metastases, and current chemotherapy does not adequately treat or protect patients with MM against CNS metastases. Therefore, the authors initiated a Phase I study to determine the pha

Long-term outcomes of thymosin-α1 and in
Long-term outcomes of thymosin-α1 and interferon α-2b combination therapy in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B
✍ Murat Saruc; Nuri Ozden; Nurten Turkel; Semin Ayhan; Lynette M. Hock; Isil Tuzcu 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 179 KB 👁 1 views

Hepatitis B e antibody (HbeAb) and hepatitis B virus (HBV) DNA positive chronic hepatitis is a clinical entity, distinct from classical hepatitis B e antigen (HbeAg) positive chronic hepatitis B. Our aim was to evaluate the long-term therapeutic efficacy of the combination of interferon alpha-2b and

Immunomodulatory effects of high-dose an
Immunomodulatory effects of high-dose and low-dose interferon α2b in patients with high-risk resected melanoma : The E2690 laboratory corollary of Intergroup Adjuvant Trial E1690
✍ John M. Kirkwood; Thomas Richards; Hassane M. Zarour; Jeffrey Sosman; Marc Ernst 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 177 KB

## Background: The clinical antitumor activity of recombinant interferon alpha2b (ifnalpha2b) has been well documented in patients with advanced and high-risk melanoma; however, its mechanism of action remains conjectural. trial e2690 evaluated the immunomodulatory effects of ifnalpha2b in vivo dur